Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 148 results for "Tecfidera Treated Patients"

Long-Term Study Supports Benefits of Treating MS at First Possible Signs
Neurology Today

Long-Term Study Supports Benefits of Treating MS at First Poss...

An 11-year follow-up study of patients with clinically isolated syndrome indicates that early treatment with interferon beta-1b had a long-lasting, even remote beneficial effect on disease activity as well as cognitive outcomes, resource ... Neurology Today, 1 month ago

New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting

− TECFIDERA Treatment Significantly Reduced Time to First Relapse vs. Glatiramer Acetate, Interferon β and Teriflunomide and Showed Comparable Efficacy to Fingolimod in Data Analysis from MSBase Registry − − Benefit-Risk Profile of ... week ago Tecfidera® real-world studies affirm sustained efficacy and safety profile  Hospital Pharmacy Europe3 days ago BIOGEN : New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting  4 Traders1 week ago Biogen Release: New Data Affirm Strong Efficacy And Well-Characterized Safety Profile Of TECFIDERA In Both Clinical Studies And Real-World Setting  BioSpace1 week ago

Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials

The new data will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in London. Using data sourced from the global MSBase registry and propensity score matching, researchers compared relapse ...
 Nasdaq1 week ago Biogen says real-world data affirm positive effects of MS drug Tecfidera seen in clinical trials  FirstWord Pharma1 week ago Biogen reports positive data for MS drug Tecfidera in clinical, real-world settings  FirstWord Pharma1 week ago

Biogen aims real-world data at Tecfidera's patient drop-out problem

Biogen's multiple sclerosis drug Tecfidera has a problem: Arelatively high number of patients start the drug, only to stop taking it later. But now, the company hastrotted out some real-world data it thinks can help turn that problem around. The ...
 FiercePharma5 days ago Biogen takes on Tecfidera adherence issues  pharmaphorum1 week ago

Orphan designation: Dimethyl fumarate, for the: Treatment of bullous pemphigoid

orphan designation (EU/3/16/1698) was granted by the European Commission to Immungenetics AG, Germany, for dimethyl fumarate for the treatment of bullous pemphigoid. What is bullous pemphigoid? Bullous pemphigoid is an autoimmune skin disease ...
 European Medicines Agency2 weeks ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 8, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago
Motley Fool

An Investing Overview of the Multiple Sclerosis Market

Image source: . The market for multiple sclerosis drugs is worth $19 billion annually and treatment advances could lead to significant shifts in market share. Can market share Goliath Biogen ( NASDAQ:BIIB ) sidestep competitive risk? Or, will ...
 Motley Fool2 months ago

Roche's MS hopeful Ocrevus banks more data for fierce market-share combat

Roche's much anticipated multiple sclerosis drug ocrelizumab trounced a standard treatment, Rebif, in a new analysis of phase III data, adding to competitive stats that could prove an edge in the hotly contested market. Now dubbed Ocrevus, ...
 FiercePharma1 week ago

Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval

The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism: Eliquis (apixaban) from ...
 DrugInjuryLaw.com1 month ago

Biogen pays $75M to Ionis on early PhIII antisense results

Biogen ($BIIB) has clocked a win on Phase III data for nusinersen to treat rare, severe genetic disease spinal muscular atrophy (SMA) with partner Ionis Pharmaceuticals ($IONS). The trial was unblinded early at an interim endpoint due to significant ...
 FierceBiotech1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less